Adrenocortical Oncocytic Tumors: Report of 10 Cases and Review of the Literature
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Ten additional adrenocortical oncocytic tumors are presented: 2 benign oncocytomas, 4 borderline oncocytomas of uncertain malignant potential, and 4 oncocytic carcinomas. Histologically all tumors were entirely or predominantly composed of oncocytes. Immunohistochemically all tumors were immunoreactive for mitochondrial antigen mES-13. Electron microscopy was performed in 8 cases and was confirmatory of the oncocytic cell change. The morphologic parameters of the Weiss system, considered to be predictive of the biologic behavior of conventional (nononcocytic) adrenocortical tumors, are reviewed in the context of their possible application to the oncocytic tumor variant. Proposed major criteria (high mitotic rate, atypical mitoses, venous invasion) and minor criteria (large size and huge weight, necrosis, capsular invasion, sinusoidal invasion) in distinguishing malignant tumors are discussed, and definitional criteria (predominantly cells with eosinophilic and granular cytoplasm, high nuclear grade, diffuse architectural pattern) in common with all types of oncocytic tumors are outlined. The authors’ proposed working rules for diagnostic categorization of oncocytic adrenocortical tumors are defined, with the presence of 1 major criterion indicating malignancy, 1 to 4 minor criteria indicating uncertain malignant potential (borderline), and the absence of all major and minor criteria indicative of benignancy. Using these criteria, the diagnosis of malignancy was straightforward in 3 of the 4 cases designated as oncocytic carcinoma (presence of at least 2 major criteria and all the minor criteria), while in 1 case the original diagnosis of benign oncocytoma was reversed to malignant following critical review of the original pathologic material after local tumor recurrence. Tumor recurrence occurred in 2 carcinomas at 8 and 20 months, respectively, and was followed in 1 case by the patient’s death. The third patient expired at 6 months from unrelated causes, and the fourth patient is free of disease at the relatively short follow-up interval of 6 months. Regarding the 4 patients with borderline tumors, all are alive with no evidence of disease, with follow-up ranging from 10 to 61 months (mean 38.7 months). The 2 benign tumors have a follow-up of 25 and 30 months, respectively. Diagnostic difficulties are delineated and a complete review of the literature on this topic has also been performed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Firminger, H. I. (1968) · Armed Forces Institute of Pathology eBooks · Cited by 3,044
Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors
Weiss, L. M. (1984) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198403000-00001 · Cited by 920 · cited 2×
“In order to assess tumor behavior and clinical prognosis, each case was morphologically evaluated according to the 9 histologic parameters of the Weiss system used for discriminating benign from malignant conventional adrenocortical tumors [4].”
BackgroundMethodSelf-citationPathologic features of prognostic significance in adrenocortical carcinoma
Weiss, L. M., Medeiros, L. J., & Vickery, A. L. (1989) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198903000-00004 · Cited by 818 · cited 1×
“The presence of 2 of these criteria is considered allowable in benign tumors while the presence of ≥3 criteria is suggestive of malignancy [32,34].”
BackgroundSelf-citationLuton, J.-P., Cerdas, S., Billaud, L., Thomas, G., Guilhaume, B., Bertagna, X., Laudat, M.-H., Louvel, A., Chapuis, Y., Blondeau, P., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004263221705 · Cited by 717
Aubert, S., Wacrenier, A., Leroy, X., Devos, P., Carnaille, B., Proye, C., Wemeau, J. L., Lecomte-Houcke, M., & Leteurtre, E. (2002) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200212000-00009 · Cited by 378
Morphologic characteristics of benign and malignant adrenocortical tumors
Slooten, H. V., Schaberg, A., Smeenk, D., & Moolenaar, A. J. (1985) · Cancer · doi:10.1002/1097-0142(19850215)55:4<766::aid-cncr2820550414>3.0.co;2-7 · Cited by 326
Hough (1979) · doi:10.1093/ajcp/72.3.390 · Cited by 320
Oncocytic Adrenocortical Neoplasms: A Report of Seven Cases and Review of the Literature
Lin, B. T.-Y., Bonsib, S. M., Mierau, G. W., Weiss, L. M., & Medeiros, L. J. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199805000-00012 · Cited by 128
Self-citationNew Developments in the Pathologic Diagnosis of Adrenal Cortical Neoplasms: A Review
Medeiros, L. J., & Weiss, L. M. (1992) · American Journal of Clinical Pathology · doi:10.1093/ajcp/97.1.73 · Cited by 124
Self-citationImmunohistochemical assessment of proliferative activity in adrenocortical neoplasms.
Goldblum, J. R., Shannon, R., Kaldjian, E. P., Thiny, M. T., Davenport, R. D., Thompson, N. W., & Lloyd, R. V. (1993) · PubMed · Cited by 116
Hoang, M. P., Ayala, A. G., & Albores‐Saavedra, J. (2002) · Modern Pathology · doi:10.1038/modpathol.3880638 · Cited by 115
Sasano, H., Suzuki, T., Sano, T., Kameya, T., Sasano, N., & Nagura, H. (1991) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199110000-00005 · Cited by 90
Adrenocortical Neoplasms: Role of Prognostic Markers MIB-1, P53, and RB
Vargas, M. P., Vargas, H. I., Kleiner, D. E., & Merino, M. J. (1997) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199705000-00008 · Cited by 90
Chromophobe Cell Carcinoma: Analysis of Five Cases
Bonsib, S. M., & Lager, D. J. (1990) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199003000-00007 · Cited by 90
Oncocytic Adrenal Cortical Carcinoma
El‐Naggar, A. K., Evans, D. B., & Mackay, B. (1991) · Ultrastructural Pathology · doi:10.3109/01913129109016262 · Cited by 90
Intriguing Case: Oncocytic Adrenal Cortical Adenoma
Erlandson, R., & Reuter, V. (1991) · Ultrastructural Pathology · doi:10.3109/01913129109016261 · Cited by 77
Non-hormonal adrenocortical adenoma with oncocytoma-like appearances.
Kakimoto, S., Yushita, Y., Sanefuji, T., Kondo, A., Fujishima, N., Kishikawa, M., & Matsumoto, K. (1986) · PubMed · Cited by 70
A small adrenocortical carcinoma with aggressive behavior. An evaluation of criteria for malignancy.
Gandour, M. J., & Grizzle, W. E. (1986) · PubMed · Cited by 44
Adrenocortical oncocytoma: Case report with immunocytochemical and ultrastructural study
Bégin, L. R. (1992) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/bf01606884 · Cited by 43
Kitching, P. A., Patel, V., & Harach, H. R. (1999) · Journal of Clinical Pathology · doi:10.1136/jcp.52.2.151 · Cited by 38
Adrenocortical oncocytoma: two case reports and review of literature
Waters, P. R., Haselhuhn, G. D., Gunning, W. T., Phillips, E. R., & Selman, S. H. (1997) · Urology · doi:10.1016/s0090-4295(96)00543-2 · Cited by 34
Ultrastructure of Adrenal Cortical Carcinoma
Mackay, B., El‐Naggar, A. K., & Ordóǹez, N. G. (1994) · Ultrastructural Pathology · doi:10.3109/01913129409016288 · Cited by 34
Hyperplasia and neoplasia of the adrenal gland.
Kay, S. (1976) · PubMed · Cited by 28
Adrenocortical Oncocytoma: Case Report and Review of the Literature
Macchi, C., Rebuffat, P., Blandamura, S., Piazza, M., Macchi, V., Fiore, D., & Nussdorfer, G. G. (1998) · Tumori Journal · doi:10.1177/030089169808400318 · Cited by 24
ADRENAL CORTICAL CARCINOMA: A clinicopathological and Immunohistochemical Study of 91 Autopsy Cases
Nakano, M. (1988) · Acta Pathologica Japonica · doi:10.1111/j.1440-1827.1988.tb01095.x · Cited by 23
Adrenocortical oncocytoma in pregnancy
Segal, S. (2001) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(01)01320-5 · Cited by 16
Icard, P., Louvel, A., Charpentier, M. L., et al. (2001) · Annales de Chirurgie · doi:10.1016/s0003-3944(01)00497-7 · Cited by 9
Cited by
Fassnacht, M., Dekkers, O. M., Else, T., Baudin, E., Berruti, A., de Krijger, R. R., Haak, H. R., Mihai, R., Assie, G., & Terzolo, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0608 · Cited by 961
Else, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1029 · Cited by 892
Overview of the 2022 WHO Classification of Adrenal Cortical Tumors
Mete, O., Erickson, L. A., Juhlin, C. C., de Krijger, R. R., Sasano, H., Volante, M., & Papotti, M. G. (2022) · Endocrine Pathology · doi:10.1007/s12022-022-09710-8 · Cited by 343
Validation of the prognostic role of the “Helsinki Score” in 225 cases of adrenocortical carcinoma
Duregon, E., Cappellesso, R., Maffeis, V., Zaggia, B., Ventura, L., Berruti, A., Terzolo, M., Fassina, A., Volante, M., & Papotti, M. (2017) · Human Pathology · doi:10.1016/j.humpath.2016.09.035 · Cited by 98
“) having a specific interest in endocrine pathology and classified according to the appropriate diagnostic systems, ie, Weiss Score [1] and Revised Weiss Score [2] for conventional ACC, LinWeiss-Bisceglia System [10] for pure oncocytic adrenocortical tumors and Wienecke classification [11] for pediatric tumors.”
MethodChallenges in surgical pathology of adrenocortical tumours
Erickson, L. A. (2018) · Histopathology · doi:10.1111/his.13255 · Cited by 70
“compared the nine histological parameters of the Weiss system, and found that two parameters (clear cell composition ≤25% and high nuclear grade) were present in all of the tumours, and that diffuse architecture was present in all but one of the tumours.(12) Utilizing the six remaining Weiss parameters (mitotic rate o…”
BackgroundMethodInfluential
Metadata
- Authors
- Bisceglia, M., Ludovico, O., Di Mattia, A., Ben-Dor, D., Sandbank, J., Pasquinelli, G., Lau, S. K., & Weiss, L. M.
- Venue
- International Journal of Surgical Pathology
- Publisher
- SAGE Publications
- Published
- 2004-07
- Volume
- 12
- Issue
- 3
- Pages
- 231-243
- ISSN
- 1066-8969 (ISSN-L)
- 1940-2465
- OpenAlex
- W2145354163
- Cited by
- 318
- References
- 27
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.